Tempus HRD-RNA is an AI-driven, 1,660-gene logistic regression model designed to identify patients likely to respond to ...

Tempus AI (NasdaqGS:TEM) has launched a new AI-driven HRD-RNA algorithm aimed at improving cancer diagnostics. The company has entered a partnership with Median Technologies to bring advanced lung ...

Tempus AI recently reported full-year 2025 results, with revenue rising to US$1.27 billion and net loss narrowing to US$245.03 million, alongside 83% year-over-year Q4 growth driven by diagnostics. At ...

Tempus AI Inc. TEM shares are up on Thursday as Mizuho initiated coverage on the health care-focused artificial intelligence ...

Tempus AI TEM rose on Wednesday after the company unveiled its new HRD-RNA algorithm, an AI-driven tool designed to improve ...

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, ...

Tempus AI launched its HRD-RNA algorithm, an AI-driven model for identifying Homologous Recombination Deficiency in cancer patients. The company also partnered with Median Technologies to integrate ...

Investing.com -- Tempus AI, Inc. (NASDAQ:TEM) stock rose 3.5% Wednesday after the precision medicine technology company announced the launch of its new HRD-RNA algorithm for cancer detection.

A machine learning algorithm used gene expression profiles of patients with gout to predict flares. The PyTorch neural network performed best, with an area under the curve of 65%. The PyTorch model ...